Watne K, Hannisdal E, Nome O, Hager B, Wester K, Heier M, Hirschberg H
Department of Medical Oncology and Radiology, Norwegian Radium Hospital, Oslo.
J Neurooncol. 1992 Sep;14(1):73-80. doi: 10.1007/BF00170947.
Seventy-five patients harboring astrocytomas received 4 cycles of infra-ophthalmic carotid injections of BCNU, combined with vincristine intravenously and procarbazine orally. All of the patients thereafter, received radiation therapy. The five year survival was 73% for all patients. The age of the patients had no significant impact on survival. The treatment results were compared with the results of 57 patients with astrocytomas who were treated with surgery followed by radiation in the same period. These 57 patients had a 5 year survival of 45% with a five year survival in patients < or = 40 years and patients > 40 years of 70% and 22%, respectively (p < 0.05). In multivariate survival analysis of the BCNU group and radiation group together, treatment group and corticosteroid dependency were the only prognostic factors. No leukoencephalopathy was seen during the treatment or in the follow-up of the patients. We conclude that pre-radiation intra-arterial chemotherapy can be given without significant morbidity and produces an improvement in survival in patients older than 40 years.
75例患有星形细胞瘤的患者接受了4个周期的经眼动脉注射卡氮芥治疗，同时静脉注射长春新碱并口服丙卡巴肼。此后，所有患者均接受了放射治疗。所有患者的5年生存率为73%。患者的年龄对生存率没有显著影响。将治疗结果与同期57例接受手术治疗后再进行放射治疗的星形细胞瘤患者的结果进行了比较。这57例患者的5年生存率为45%，年龄≤40岁和＞40岁患者的5年生存率分别为70%和22%（p＜0.05）。在对卡氮芥组和放射组进行的多因素生存分析中，治疗组和皮质类固醇依赖是仅有的预后因素。在患者治疗期间或随访过程中未观察到白质脑病。我们得出结论，放疗前动脉内化疗可在无明显并发症的情况下进行，并能提高40岁以上患者的生存率。
